Kornimate/medical-research-clean huggingface dataset:
pediatric out-of-hospital cardiopulmonary arrest

Conditions: Pediatric; Cardiac Arrest; Out-Of-Hospital Cardiac Arrest

Summary: the objective of this observational and retrospective study is to determine the predictive factors of in-hospital mortality following an out-of-hospital cardiopulmonary arrest (cpa) in the population under 18 years old. data are collected from telephone calls and medical regulation records processed by the health call center of 2 french departments between january 1, 2019, and march 15, 2022. the medical records of the included patients will also be reread in order to obtain the patient's status at 30 days after the cpa. detailed description: the literature reports numerous works evaluating the epidemiological characteristics of pediatric out-of-hospital cardiorespiratory arrest. an improvement in survival has been reported in the case of resuscitation guided by the operator in medical regulation before the arrival of the emergency services. indeed, the regulation phase at the 15 center in france is of fundamental importance. recent evolutions, notably with the creation of specific call-taking professions, show the importance attached to improving practices. the population concerned is characterized by children under 18 years of age, victims of an extra-hospital cardiorespiratory arrest. it is a retrospective study over three years and three months, multicentric, from the emergency service (samu) 57 and 69. the primary endpoint was the all-cause mortality at thirty days of the admission. the case report form (crf) will collect the main aspects of telephone management at the 15 centers, out-of-hospital management by the emergency teams, and the personal characteristics of the emergency physicians and out-of-hospital responders (gender, age, family situation, etc.). the medical management in the emergency department and the first stages of in-hospital management will also be analyzed. the patients included who are still alive will receive a notification of non-objection by mail.


Eligibility criteria:
inclusion criteria: * child under 17 years old * and call for cardiac arrest or cardiac arrest detected on call exclusion criteria: * non-real cardiac arrest
restoring central motor control extension

Conditions: Gait, Unsteady

Summary: motor skill training therapy aims to improve the brain's control of walking and can improve clinic-based measures of walking in older adults. however, it is unknown whether the benefits of motor skill training extend to real world mobility measures. the investigators will test the effects of motor skill training on measures of community mobility of older adults and assess the mechanisms through improved motor control at the level of the brain. these results will inform intervention approaches to maintain community mobility of older adults and prevent disability and institutionalization.


Eligibility criteria:
inclusion criteria: * 65 years of age and older * ambulatory without an assistive device or the assistance of another person * usual 4 meter gait speed \> 0.60 m/s and \< 1.2 m/s * physician clearance to participate in a moderate intensity exercise program * not meeting physical activity recommendations defined as reporting less than 150 minutes of moderate intensity activity per week in the past month. exclusion criteria: * persistent lower extremity pain that is present on most days of the week * back pain that is present on most days of the weeks and interferes with walking and - activities of daily living or back pain that increases with walking * refuse to walk on a treadmill * plans to move out of the area in the next 5 years * dyspnea at rest or during activities of daily living or use supplemental oxygen (chf, copd) * any acute illness or medical condition that is not stable according to the approving physician * resting systolic blood pressure ≥ 200 mm hg or diastolic blood pressure ≥ 100 mm hg or resting heart rate \> 100 or \< 40 beats per minute * diagnosed dementia or cognitive impairment defined as modified mini-mental state (3ms) examination \<79 * hospitalized in the past 6 months for acute illness or surgery, other than minor surgical procedures * severe visual impairment f- ixed or fused lower extremity joints such as hip, knee or ankle * lower extremity strength \<3/5 on manual muscle testing * lower extremity amputation * progressive movement disorder such as multiple sclerosis, amyotrophic lateral sclerosis or parkinson's disease
a study of paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics

Conditions: Schizophrenia

Summary: the purpose of this study is to assess the effectiveness, safety and tolerability of flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics and with acute symptom of schizophrenia.

this is a 13-week, open-label (all people know the identity of the intervention), single-arm (one group of patients), multicenter, prospective, interventional study in chinese patients. in a prospective, interventional study, the patients identified receive a treatment during the course of the research study and are followed forward in time for the outcome of the study. in china, there is still insufficient information about effectiveness, tolerability, and dosage strategy for directly switching from previous oral antipsychotics (drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders) in patients with acute symptoms. acute symptoms are quick and severe form of illness in its early stage. in addition, there is also lack of information about bridging acute phase to long-term treatment. in this study, patients with multiple types of acute schizophrenia will be recruited and will receive sustenna (paliperidone palmitate) treatments for 13 weeks. after the acute treatment, the patients will continue to receive the prescribed medication and will be followed up for an additional 52 weeks to assess the outcomes related to long-term treatment.

Eligibility criteria:
inclusion criteria: * previous diagnosis of schizophrenia * experiencing an acute episode, with a positive and negative syndrome scale (panss) total score between 70 and 120, inclusive * patients currently treated with antipsychotic are allowed to be recruited * be medically stable on the basis of clinical laboratory tests performed at screening exclusion criteria: * a primary diagnosis other than schizophrenia * history of risperidone or paliperidone resistance as defined by failure to respond to 2 adequate treatment periods * clozapine use for treatment refractory schizophrenia * relevant history or current presence of any significant or unstable condition, disease or illness that could limit the participation in the study according to the investigator * woman who is pregnant, breast-feeding, or is planning to become pregnant within 6 months

Keywords: schizophrenia paliperidone palmitate oral antipsychotics invega sustenna
impact of hospital pharmacist intervention on medication management in dialysis patients

Conditions: Renal Dialysis; Health Literacy Level; Kidney Disease, Chronic

Summary: the goal of this clinical trial is to learn if an intervention of a hospital pharmacist could help, dialysis patients managed his treatment. in a first time, the health literacy level will be assed. the main questions it aims to answer are: what is the impact of the clinical pharmacist intervention on the understanding level and management level of his treatment by the patient? does the intervention of the pharmacist has an effect on the biologicals parameters of the patient? researchers will compare a group with a pharmacist intervention vs a group without pharmacist intervention for dialysis patients.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age * on dialysis (peritoneal dialysis, hemodialysis) for at least 3 months * prescription for at least 5 daily medications * patient who has not received any pharmaceutical consultation from a hospital pharmacist as part of his or her treatment for chronic renal failure. exclusion criteria: * patient does not speak and/or understand french * patient's cognitive state does not permit an interview * patient not autonomous in managing his or her daily medication (e.g.: patient in nursing home) * patient refusal

Keywords: clinical pharmacist end stage renal disease
early screen and treatment for gestational diabetes

Conditions: Gestational Diabetes

Summary: in the current study we aim to determine if early glucose screening and treatment among women at high risk for gdm improves perinatal outcome and decreases gestational weight gain. half of the participant will be assigned to an early glucose screen group (12-18 weeks) and treatment if necessary and the other half to a standard 24-28 weeks glucose screen.


Eligibility criteria:
inclusion criteria: pregnant subjects 18-45 y/o and any of the following: obesity defined as having a bmi\>30 kg/m2 history of pregnancy complicated with gdm history of pregnancy complicated with macrosomia first degree relative with diabetes multiple gestation exclusion criteria: * incomplete data: if any data is missing (i.e delivery data) , analysis cannot be completed. pregnancy complicated with fetal malformations or aneuploidy: it affects prenatal care, mode of delivery as well as perinatal outcome. pregestational or overt diabetes: patients with diabetes cannot be diagnosed with gdm. chronic medical conditions such as hypertension, renal disease, autoimmune conditions: those conditions may affect prenatal care, perinatal morbidity. early diabetes screen performed prior to enrollment in study: participant cannot be randomized, and probably have been treated. medical contraindication to glucose tolerance test (bariatric surgery): patients with h/o gastric bypass frequently cannot tolerate oral glucose load, therefore cannot be screened for gdm in the traditional way.

Keywords: early glucose screen, perinatal outcome
a pilot study to examine the feasibility and effect of tumor necrosis factor (tnf) inhibition on hiv disease

Conditions: HIV Infections

Summary: this pilot study will investigate the safety and effect of etanercept in hiv infection by studying hiv replication and immune function (as measured by cd4 counts) in individuals with hiv infection.


Eligibility criteria:
inclusion criteria: * adults greater than 18 years of age with documented hiv infection * highly active antiretroviral therapy (haart) regimens as defined by the department of health and human services guidelines; stable regimens for 12 weeks. * cd4 greater than 200 at time of study enrollment * stable monitoring labs (hematology survey with differential, alt, creatinine) * absolute neutrophil count within normal limits exclusion criteria: * aids defining illness within the last 6 months * acute bacterial, viral, or fungal infection within the last 1 month, or history of recurring infections * women who are pregnant or nursing * hypersensitivity to etanercept * previous use of etanercept * acute malignancy in the last 5 years excluding in situ cervical cancer (ca) and common skin cancers (non melanoma) * history of active or latent tuberculosis * history of demyelinating nerve disease * history of seizure disorder * latex allergy * subject has any of the following laboratory values within 30 days of baseline: * hemoglobin concentration \< 10.0 g/dl for men and \< 9.0 g/dl for women * platelet count \< 75,000/mm3 * ast or alt \> 5x upper limit of normal (uln) * serum creatinine \> 2.5x uln * serum pancreatic amylase \> 1.5 uln * subject requiring treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferon * subjects who chronically use any over-the-counter (otc) or prescription medication (except vitamins) must not change the regimen or switch their medication within 3 days of drug administration and until discharged from the study.

Keywords: hiv
thrombosomes® in acute thoracic aortic dissections

Conditions: Thoracic Aortic Dissection

Summary: the hypothesis is that administration of thrombosomes® (tbx®) as hemostatic support when terminating the cardiopulmonary bypass (cpb) in patients undergoing emergency surgery for acute thoracic aortic dissection (atad) is safe and least as effective when compared to standard platelet concentrates (stpc).

the study is designed as an exploratory phase 2a, single-center randomized, controlled pilot investigator-initiated trial of administration of thrombosomes® (tbx®) versus standard platelet concentrates (stpc) in 20 atad patients per arm. the patients will be enrolled in the study over a period of 15 months. tbx® is a novel, human platelet (thrombocyte) derived lyophilized (freeze dried) hemostatic blood product for treatment of bleeding due to thrombocytopenia, dysfunctional platelet disorders or platelet consumption. the patients will be randomized to administration of either tbx®, or stpc, as part of the massive transfusion protocol (mtp) at the time of termination of the cardiopulmonary bypass (cpb) in addition to standard goal-directed hemostatic optimization based on results from thrombelastography (teg).

Eligibility criteria:
inclusion criteria: * patient eligible for emergency surgery on cardiopulmonary bypass pump for acute thoracic aortic dissections * age ≥ 18 years exclusion criteria: * documented refusal of blood transfusion * aortic dissection due to trauma * withdrawal from active therapy * known hypersensitivity to tbx: the active substance, any of the excipients * pregnancy (non-pregnancy confirmed by patient being postmenopausal (women \>55 years of age) or having a negative urine-hcg).

Keywords: surgery bleeding
mmf influence on hcv viral evolution after liver transplantation

Conditions: HCV Infection; Liver Transplantation

Summary: samples from a large clinical trial comparing three immunosuppression regimens, two of which contained mmf, are used to identify the hcv viral quasispecies behaviour after liver transplantation


Eligibility criteria:
all patients enrolled into - an open randomized, prospective multicenter study to compare the efficacy and safety among three immunosuppressant treatment regimens in patients receiving a liver transplant for end-stage liver disease caused by chronic hepatitis c infection
erector spinae plane block and oblique subcostal transverse abdominis plane block in laparoscopic cholecystectomy

Conditions: Postoperative Pain

Summary: erector spinae plane block is a newly defined regional anesthesia technique. its use for many indications has been identified by case reports in the literature. as the investigators have considered that erector spinae plane block could be efficacious for providing postoperative analgesia in laparoscopic cholecystectomy, the investigators have implemented the application of this blockade into practice at the clinic.oblique subcostal transverse abdominis plane block (ostap) is another regional anesthesia technic used for postoperative analgesia in laparoscopic cholecystectomy. main purpose of this study is to compare the analgesic effect of ultrasound-guided erector spinae block and ostap in laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: -elective laparoscopic cholecystectomy, asa status 1-2 - exclusion criteria: * patient refusal * contraindications to regional anesthesia * known allergy to local anesthetics * bleeding diathesis * use of any anti-coagulants * inability to provide informed consent * severe kidney or liver disease * inability to operate pca system * patient with psychiatric disorders
prospective study about sensitization pattern to insects as food source in patients with house dust mite allergy

Conditions: Hypersensitivity, Food

Summary: patients allergic to seafood and/or sensitized to tropomyosin of skin prick tests spt or crustacean origin will may be also be sensitized to edible insects. aim of the study is to evaluate whether patients allergic to seafood and/or sensitized to tropomyosin of spt or crustacean origin may be more often be sensitized to edible insects used as food source.

house dust mite allergy is a common problem in europe. in addition to inhalant allergies sensitization to mites can be related to food allergy namely seafood. insects are also widespread food sources in many regions of the world. in this study skin testing and laboratory tests are planned in patients with known house dust mite allergy to evaluate a possible sensitization to insects. patients must also complete a questionnaire. a drug therapy or other intervention is not planned. aim of the study is to evaluate whether patients allergic to seafood and/or sensitized to tropomyosin of spt or crustacean origin may be more often be sensitized to edible insects used as food source.

Eligibility criteria:
inclusion criteria: * age: 18 \< x \< 70 * house dust mite sensitization with or without sensitization to seafood * subject is capable of giving informed consent * signed informed consent exclusion criteria: * use of antihistamines, systemic corticosteroids during testing and within three days (antihistamines) or two weeks (corticosteroids) prior to testing * use of immunosuppressive agents * history of cancer except for treated basal cell or spinal cell carcinoma of the skin * active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of human immunodeficiency virus (hiv) infection, hepatitis b and hepatitis c infection, active or untreated latent tuberculosis. * female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial * known or suspected non-compliance, drug or alcohol abuse, * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * previous enrollment into the current study, * enrollment of the investigator, his/her family members, employees and other dependent persons,
the sensitivity and specificity of canine detection of parkinson's disease

Conditions: Parkinson Disease

Summary: people sometimes report that their relatives who have been diagnosed with parkinson's disease (pd) have a unique smell. a previous study has demonstrated that pd patients do have smell that is different from that of healthy people. sniffer dogs have long been used to identify criminals, and recently been used to identify subject with cancer. the investigators hypothesized that sniffer dogs may be able to identify pd patients.

parkinson's disease is a neurodegeneration disorder that affects the life of millions of people worldwide. there are multiple drugs available now that can modify the process of the disease. making a timely and correct diagnosis of pd is still a great challenge in many cases even for specialists. correct diagnosis is fundamental to the appropriate administration of medicines. to help clinicians to quickly and correctly make a diagnosis, the investigators aim to use sniffer dogs to identify pd patients from clearly non-pd subjects. after more than one-year training of the dogs, the investigators found that it is feasible to use dogs to identify pd patients from non-pd subjects. now the investigators are trying to estimate the sensitivity and specificity of sniffer dogs in identifying pd patients from non-pd subjects. in this multicenter study, the clinicians and their assistants will collect samples and send to the study center. one researcher alone will put seven plastic bags containing matched samples (one pd sample and six non-pd samples) on a table and take notes, then relabel them with random numbers and take notes again, and keep them in a confidential place till the study is completed. another researcher will take over the relabeled samples and put them into different tanks and take notes. thus, both the experimenter who helps to place the samples into tanks and the dog handler will not know the nature of the samples. test results will be compared with the notes of the blind-setter after all the experiments have been performed. the sensitivity and specificity of identification will be calculated. the study aims to test the hypothesis that the diagnostic sensitivity of sniffer dogs in identifying pd patients from non-pd subjects is over 90%.

Eligibility criteria:
inclusion criteria: * clinically established pd patients * clearly non-pd subjects will be recruited as controls exclusion criteria: * subjects with tremor or decrease of olfactory power or with rapid eye movement sleep behavior, obvious constipation, and depression. * subjects who are taking antipsychotics. * subjects with incomplete data.
breast/evaluation of cryotherapy and trpa1 receptors in chemotherapy induced neuropathy

Conditions: Peripheral Neuropathies

Summary: to determine rate and severity of chemotherapy induced neuropathy in extremities treated with cold gloves and socks versus control extremities

this is a therapeutic study investigating the use of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy (cipn) and associated nail toxicities. the therapeutic intervention will involve patients wearing an elasto-gel cold glove and sock on one hand and one foot (both on the right side or both on the left side). the patients will wear the glove and sock during each infusion of taxane chemotherapy.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of early stage breast cancer (stage i-iii). * planned to receive treatment with either adjuvant or neo-adjuvant taxane-based chemotherapy. * age \> 18 years. there is no upper age limit for participation in this study. * patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation. * prior chemotherapies are permitted, except with prior treatments with taxanes, vinca alcaloids, gemcitabine, eribulin, ixabepilone, platinum drugs) * all patients will have given signed, informed consent prior to registration * patients must have a performance status of ecog 0 or 1. exclusion criteria * patients must not have received any prior taxane or platinum based chemotherapy. * patients must not have a history of peripheral neuropathy (regardless of cause). * patient must not have a history of raynaud's disease. * patients with partial or complete limb amputations. * known hypersensitivity to cold * patient cannot be on the following medications: gaba analogues (such as neurontin, lyrica), tricyclic antidepressants (such as amitriptyline or nortriptyline) * as judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements. * evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participant in the clinical trial * must not be pregnant or breast feeding